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Abstract  
  
Ophthalmologic  manifestations  of  mitochondrial  disorders  are  frequently  neglected  or  
overlooked  because  they  are  often  not  regarded  as  part  of  the  phenotype.  This  
review  aims  at  summarizing  and  discussing  the  etiology,  pathogenesis,  diagnosis,  
and  treatment  of  ophthalmologic  manifestations  of  mitochondrial  disorders.  Review  of  
publications  about  ophthalmologic  involvement  in  mitochondrial  disorders  by  search  
of  Medline  applying  appropriate  search  terms.  The  eye  is  frequently  affected  by  
syndromic  as  well  as  nonsyndromic  mitochondrial  disorders.  Primary  and  secondary  
ophthalmologic  manifestations  can  be  differentiated.  The  most  frequent  
ophthalmologic  manifestations  of  mitochondrial  disorders  include  ptosis,  progressive  
external  ophthalmoplegia,  optic  atrophy,  retinopathy,  and  cataract.  More  rarely  
occurring  are  nystagmus  and  abnormalities  of  the  cornea,  ciliary  body,  intraocular  
pressure,  the  choroidea,  or  the  brain  secondarily  affecting  the  eyes.  It  is  important  to  
recognize  and  diagnose  ophthalmologic  manifestations  of  mitochondrial  disorders  as  
early  as  possible  because  most  are  accessible  to  symptomatic  treatment  with  partial  
or  complete  short-­term  or  long-­term  beneficial  effect.  Ophthalmologic  manifestations  
of  mitochondrial  disorders  need  to  be  appropriately  diagnosed  to  initiate  the  most  
effective  management  and  guarantee  optimal  outcome  
  
     
Introduction  
Mitochondrial  disorders  manifest  phenotypically  as  mitochondrial  multiorgan  disorder  
syndrome  in  the  vast  majority  of  the  cases.1  The  degree  of  mitochondrial  multiorgan  
disorder  syndrome  can  be  assessed  by  determining  the  mitochondrial  multiorgan  
disorder  syndrome  score,  which  is  calculated  by  summing  the  number  of  affected  
organs  (range:  1-­13),  the  number  of  abnormalities  within  an  organ  (range:  1-­94),  and  
the  probability  that  an  abnormality  is  due  to  a  mitochondrial  defect  (range:  1-­3).  A  
score  >10  suggests  a  mitochondrial  disorder.  The  organs  most  frequently  affected  in  
mitochondrial  multiorgan  disorder  syndrome  are  the  skeletal  muscle,  central  nervous  
system,  peripheral  nervous  system,  endocrine  system,  heart,  ears,  and  the  eyes.  
More  rarely,  intestines,  liver,  pancreas,  kidneys,  bone  marrow,  cartilage,  or  bones  are  
affected.  Ophthalmologic  manifestations  of  mitochondrial  disorders  are  frequently  
neglected  or  overlooked  because  they  can  be  mild  and  are  frequently  not  regarded  
as  part  of  the  phenotype  but  can  be  the  dominant  phenotypic  feature  of  a  
mitochondrial  disorder.  This  review  aims  at  summarizing  and  discussing  etiology,  




Data  for  this  review  were  identified  by  searches  of  MEDLINE,  Current  Contents,  and  
references  from  relevant  articles  using  the  search  terms  ophthalmologic,  eye,  cornea,  
lens,  ciliary  body,  retina,  choroidal,  uvea,  optic  nerve,  ophthalmoparesis,  
ophthalmoplegia,  ptosis,  strabismus,  and  nystagmus  in  combination  with  
mitochondrial,  mtDNA,  oxidative  phosphorylation,  respiratory  chain,  electron  chain,  
oxidative  stress,  and  mitochondrion.  Randomized  (blinded  or  open  label)  clinical  
trials,  longitudinal  studies,  case  series,  and  case  reports  were  considered.  Abstracts  
and  reports  from  meetings  were  not  included.  Only  articles  published  in  English  
between  1966  and  2015  were  considered.  Appropriate  papers  were  studied  and  
discussed  for  their  suitability  to  be  incorporated  in  this  review.  
  
Classification  of  Ophthalmologic  Mitochondrial  Disorder  Manifestations  
Ophthalmologic  mitochondrial  disorder  manifestations  may  be  classified  according  to  
various  different  criteria.  They  may  be  categorized  as  isolated  or  nonisolated,  
occurring  in  association  with  other  organ  manifestations.  Ophthalmologic  
manifestations  may  be  the  dominant  feature  of  the  phenotype  or  a  nondominant  
feature.  Mitochondrial  disorders  with  ophthalmologic  manifestations  may  be  either  
due  to  mitochondrial  DNA  or  nuclear  DNA  mutations.  Ophthalmologic  manifestations  
may  be  specific  for  a  syndromic  mitochondrial  disorder  (eg,  Leber  hereditary  optic  
neuropathy)  or  nonspecific  (eg,  cataract).  They  may  manifest  as  the  presenting  
symptom  or  sign  or  may  follow  after  occurrence  of  other  manifestations.  
Ophthalmologic  manifestations  may  be  also  classified  according  to  the  involved  
ophthalmologic  structure  as  primary,  affecting  only  the  bulb  (eg,  cornea,  iris,  lens,  
ciliary  body,  retina,  choroidea,  uvea,  optic  nerve,  ocular  pressure),  or  as  secondary,  
affecting  structures  outside  the  bulb,  such  as  the  extraocular  eye  muscles,  the  lid  
muscles,  the  vestibular  organ,  or  the  brain  (Table  1).  
  
Primary  Ophthalmologic  Mitochondrial  Disorder  Manifestations  
  
Primary  ophthalmologic  mitochondrial  disorder  manifestations  may  involve  the  
cornea,  iris,  lens,  ciliary  body,  retina,  choroidea,  uvea,  or  the  optic  nerve.  
  
Cornea  
During  recent  years,  some  evidence  has  been  provided  that  the  cornea  can  be  
involved  in  mitochondrial  disorders.  Systematic  studies  on  this  matter,  however,  have  
not  been  conducted.  Corneal  abnormalities  associated  with  mitochondrial  dysfunction  
include  astigmatism,  corneal  dystrophy,  corneal  clouding,  or  corneal  endothelial  
dysfunction.4,5  Endothelial  dysfunction  of  the  cornea  has  been  described  in  Pearson  
syndrome  (Table  1).5  Astigmatism  (keratoconus  [thinning  of  corneal  struma])  has  
been  reported  in  nonsyndromic  mitochondrial  disorders  (Table  1).6  In  a  study  of  20  
patients,  keratoconus  was  attributed  to  increased  oxidative  stress  resulting  from  
mitochondrial  respiratory  chain  complex-­I  sequence  variations.70  In  a  patient  with  
Kearns-­Sayre  syndrome,  progressive  external  ophthalmoplegia  secondarily  led  to  
recurrent  conjunctivitis  and  keratitis.3  Despite  almost  complete  ptosis,  spontaneous  
corneal  ulceration  occurred.3  In  patients  carrying  the  3895-­bp  mitochondrial  DNA  
deletion,  the  highest  mutation  load  was  found  in  the  cornea  and  retina.71  Corneal  
clouding  due  to  structural  changes  in  the  endothelium  or  Descemet  membrane  has  
been  occasionally  reported  in  Kearns-­Sayre  syndrome.2  In  a  child  with  Leigh  
syndrome  due  to  the  mutation  m.8993T>G,  numerous  distended  mitochondria  were  
found  in  the  corneal  epithelium.7  Nonspecific  corneal  alterations  were  also  observed  
in  a  patient  with  mitochondrial  neurogastrointestinal  encephalomyopathy.8  In  a  study  
of  14  patients  with  pontocerebellar  hypoplasia,  of  which  13  carried  a  CASK  mutation,  
2  presented  with  megalocornea.9  Though  corneal  surgery  could  be  an  option  for  
astigmatism,  it  has  not  been  reported  in  a  mitochondrial  disorder  patient.  
  
Iris  
Involvement  of  the  iris  in  mitochondrial  disorders  has  been  only  rarely  documented  
and  was  particularly  described  in  mitochondrial  encephalomyopathy,  lactic  acidosis,  
and  strokelike  episodes  (MELAS)  syndrome.10  In  a  patient  carrying  the  m.3243A>G  
mutation  in  the  tRNA(Lys)  gene,  patchy  atrophy  of  the  iris  stroma  was  described.10  In  
patients  with  Leber  hereditary  optic  neuropathy,  not  only  visual  function  but  also  pupil  
responses  were  reduced  although  pupil  afferent  fibers  were  spared.11  Additionally,  
pupillary  dysfunction  has  been  reported  in  a  62-­year-­old  male  carrying  a  large  single  




The  most  frequent  of  the  lenticular  abnormalities  in  mitochondrial  disorders  is  
cataract.  Usually,  cataract  in  mitochondrial  disorders  is  of  the  posterior  subcapsular  
type.10  Cataract  can  be  a  phenotypic  feature  of  MELAS  syndrome10,13  but  has  been  
also  reported  as  initial  manifestation  in  a  patient  with  nonsyndromic  mitochondrial  
disorder  due  to  a  mitochondrial  DNA  deletion.14  In  rare  cases,  cataract  is  a  feature  of  
Leber  hereditary  optic  neuropathy,15  myoclonus  epilepsy  with  ragged  red  fibers  
(MERRF)  syndrome,  Pearson  syndrome,  Leigh  syndrome,  maternally  inherited  
deafness  and  diabetes,  progressive  external  ophthalmoplegia,  or  nonsyndromic  
mitochondrial  disorders  (Table  2).16  Cataract  is  a  typical  feature  of  autosomal  
dominant  optic  atrophy  resulting  from  OPA3  mutations.17  Rarely,  Wolfram  syndrome  
manifests  with  cataract.18  In  all  types  of  mitochondrial  disorder,  cataract  is  accessible  





The  ciliary  body  has  been  only  rarely  reported  to  be  involved  in  mitochondrial  
disorders.  In  a  patient  dying  at  age  15  months  from  Leigh  syndrome  due  to  the  
mutation  m.8993T>G  in  the  ATPase6  gene,  histopathologic  postmortem  examination  
revealed  thinning  of  nerve  fibers  and  ganglion  cell  layers  in  the  nasal  aspect  of  the  
macula,  mild  atrophy  of  the  temporal  aspect  of  the  optic  nerve  head,  and  numerous  
distended  mitochondria  in  all  cell  types,  particularly  in  the  retina,  nonpigmented  ciliary  
epithelium,  and  the  corneal  epithelium.7  Additionally,  the  ciliary  epithelium  was  
affected  in  a  patient  with  long-­chain  3-­hydroxyacyl-­CoA  dehydrogenase  deficiency.20  
  
Retina  
Retinal  manifestations  of  mitochondrial  disorders  include  various  retinal  dystrophies,  




Retinitis  pigmentosa  is  a  core  feature  of  Kearns-­Sayre  syndrome  and  neuropathy  
ataxia  retinitis  pigmentosa  syndrome.13  Typical  for  Kearns-­Sayre  syndrome  is  the  
“salt  and  pepper”  retinitis  with  regions  of  increased  and  decreased  pigmentation,  
particularly  in  the  equatorial  fundus.2  Pigmentary  retinopathy  is  only  a  rare  feature  of  
progressive  external  ophthalmoplegia  and  may  be  milder  than  in  Kearns-­Sayre  
syndrome  (Table  1).13,21  Only  some  patients  with  MELAS  or  MERRF  syndrome  
present  with  mild  pigmentary  retinopathy  of  the  posterior  pole.13  Mild  pigmentary  
defects  were  also  found  in  2  of  20  patients  with  Leber  hereditary  optic  neuropathy  
due  to  the  m.11778G>A  mutation  (Table  1).13  Small  pigmentary  retinal  defects  were  
described  in  a  4-­year-­old  female  with  COX  deficiency.22  Furthermore,  retinitis  
pigmentosa  has  been  described  in  patients  with  Leigh  syndrome  due  to  the  mutation  
m.8993T>G.23  In  a  study  of  44  Chinese  patients  with  Leigh  syndrome,  pigmentary  
retinopathy  was  even  found  in  22%.24  In  a  study  of  14  patients  with  pontocerebellar  
hypoplasia,  4  presented  with  retinopathy  without  reporting  details.9  Additionally,  
retinopathy  can  be  found  in  mitochondrial  neurogastrointestinal  encephalomyopathy  
and  nonsyndromic  mitochondrial  disorders  (Table  2).  Retinal  dystrophy  may  
occasionally  manifest  with  photophobia.  In  a  study  of  46  mitochondrial  disorder  
patients,  4  suffered  from  photophobia.  Two  patients  had  Leigh  syndrome,  of  which  1  
had  rod-­cone  dystrophy  on  electroretinography,  1  had  Kearns-­Sayre  syndrome  with  a  




Macular  dystrophy  has  been  described  in  patients  carrying  the  m.3243A>G  mutation  
in  the  tRNA(Lys)  gene.25  In  a  single  case  with  Pearson  syndrome,  parafoveal  
intraretinal  crystals  were  seen.26  Bilateral  macular  dystrophy  with  circumferentially  
distributed  perifoveal  atrophy  has  been  recognized  in  maternally  inherited  deafness  
and  diabetes  and  MELAS  syndrome  (Figure  1).27  A  rod-­cone  dystrophy  has  been  
recorded  on  electroretinography  in  a  patient  with  Kearns-­Sayre  syndrome.19  Macular  
dystrophy  was  a  common  feature  in  a  study  of  54  patients  with  maternally  inherited  
deafness  and  diabetes,  occurring  in  86%  of  them.28  Macular  dystrophy  in  these  
patients  manifests  as  either  pigmentary  lesions  or  atrophy  of  either  the  choroid  or  
retinal  pigmentary  epithelium  (Table  1).28  In  a  study  of  35  British  subjects  with  
mitochondrial  disorder,  85.7%  had  macular  changes.29  Electroretinographies  were  
reduced  in  4  of  9  patients,  and  b-­wave  responses  impaired  in  2.29  Pigmentary  
maculopathy  was  the  cause  of  poor  vision  in  a  12-­year-­old  boy  with  Wolfram  
syndrome.30  
  
Other  retinal  abnormalities  
Retinal  abnormalities  other  than  pigmentary  retinopathy  or  macular  degeneration  
include  retinal  dystrophy,  retinal  hypertrophy,  and  pigmentary  maculopathy.  Retinal  
dystrophies  can  be  most  easily  assessed  by  electroretinography  and  can  be  found  in  
patients  with  Kearns-­Sayre  syndrome,  Leigh  syndrome,  MELAS  syndrome,  MERRF  
syndrome,  and  Leber  hereditary  optic  neuropathy.19  In  patients  with  autosomal  
recessive  spastic  ataxia  with  leukoencephalopathy  and  autosomal  recessive  spastic  
ataxia  of  Charlevoix-­Saguenay  (ARSAL/ARSACS),  retinal  hypertrophy  has  been  
described.31  In  a  family  with  Mohr-­Tranebjaerg  syndrome,  6  affected  males  had  
blindness  resulting  from  nonspecified  retinal  degeneration.32  Treatment  options  for  
retinopathy  in  general  are  limited.  
  
Choroidea,  Uvea  
Choroidea  and  uvea  are  only  rarely  affected  in  mitochondrial  disorders.  The  most  
frequent  manifestation  of  mitochondrial  disorders  in  the  choroidea  is  choroidal  
atrophy.10  Choroidal  atrophy  has  been  particularly  described  in  MELAS  syndrome.10  
Atrophy  of  choroid  pigmentary  epithelium  also  occurs  in  maternally  inherited  
deafness  and  diabetes.28  Central  choroidal  dystrophy  as  confirmed  by  
electroretinography  was  reported  in  1  patient  with  Mohr-­Tranebjaerg  syndrome.32  
Additionally,  chorioretinal  dystrophy  was  reported  in  a  single  patient  carrying  a  large  
mitochondrial  DNA  deletion.33  
  
Optic  Nerve  
The  main  mitochondrial  disorder  manifestation  of  the  optic  nerve  is  optic  atrophy.  
Optic  atrophy  is  a  common  mitochondrial  disorder  manifestation  but  frequently  
missed  or  misinterpreted.  This  is  due  to  the  difficulty  diagnosing  optic  atrophy.  Optic  
atrophy  can  be  most  accurately  assessed  by  funduscopy  if  the  distal  portion  of  the  
optic  nerve  is  affected  or  by  magnetic  resonance  imaging  (MRI)  of  the  orbita  if  the  
more  proximal  parts  of  the  nerve  are  affected.  An  indication  of  optic  nerve  atrophy  is  
a  reduced  amplitude  of  visually  evoked  potentials.73  
Among  syndromic  mitochondrial  disorders,  optic  atrophy  has  been  particularly  
described  in  Leber  hereditary  optic  neuropathy  and  autosomal  dominant  optic  
atrophy,  conditions  in  which  optic  atrophy  is  the  dominant  phenotypic  feature.34  Both  
conditions  and  their  ophthalmologic  abnormalities  are  thus  described  in  more  detail  in  
the  section  “Mitochondrial  Disorders  Primarily  Manifesting  in  the  Eye.”  More  rarely,  
optic  atrophy  has  been  reported  in  MELAS  syndrome,  Kearns-­Sayre  syndrome,  
Pearson  syndrome,  pontocerebellar  hypoplasia,  Mohr-­Tranebjaerg  syndrome,  
Alpers-­Huttenlocher  disease,  or  Wolfram  syndrome.2,9,19,34  Partial  or  total  optic  
atrophy  also  has  been  reported  in  patients  with  MERRF  syndrome.13,19,35  Optic  
atrophy  is  a  typical  phenotypic  feature  of  hereditary  motor  and  sensory  neuropathy  
type  VI  (HMSN-­IV)  due  to  MFN1  mutations.34  Additionally,  C12orf65  (COXPD7)  
mutations  manifest  phenotypically  with  optic  atrophy  and  a  Leigh-­like  phenotype.36  
Only  in  a  single  family  was  optic  atrophy  associated  with  neuropathy  ataxia  retinitis  
pigmentosa  syndrome  due  to  the  m.8993T>G  mutation  in  the  ATPase6  gene.37  In  a  
study  of  44  Chinese  patients  with  Leigh  syndrome,  optic  atrophy  was  described  in  
22.5%.24  Only  in  a  single  patient  with  mitochondrial  neurogastrointestinal  
encephalomyopathy,  optic  disc  alterations  were  observed.8  Optic  atrophy  can  also  be  
a  feature  of  infantile-­onset  spinocerebellar  ataxia38  or  mitochondrial  depletion  
syndrome.39  Nonsyndromic  mitochondrial  disorders  with  optic  atrophy  were  due  to  an  
ACI1  mutation,40  due  to  an  ND5  mutation  together  with  cataract  and  retinopathy,41  or  
due  to  an  unknown  genetic  cause.42  Optic  atrophy  is  not  accessible  to  treatment.  
  
Intraocular  Pressure  
Increased  intraocular  pressure  (glaucoma)  is  a  rare  phenotypic  feature  of  
mitochondrial  disorders.  Two  main  types  of  glaucoma  can  be  differentiated,  open-­
angle  glaucoma  and  closure-­angle  glaucoma.  Additionally,  normotensive  and  
hypertensive  glaucoma  is  differentiated.  Rarely,  open-­angle  glaucoma  can  be  found  
in  patients  with  Leber  hereditary  optic  neuropathy43  or  autosomal  dominant  optic  
atrophy  (Table  1).  Funduscopic  findings  may  show  a  mixture  of  abnormalities  typical  
for  glaucomatic  retinopathy  and  a  Leber  hereditary  optic  neuropathy  fundus.  
Glaucomatous  changes  of  the  optic  disc  were  found  by  visual  field  examination  and  
optical  coherence  tomography  in  a  single  patient  with  mitochondrial  
neurogastrointestinal  encephalomyopathy.8  In  a  study  of  14  patients  with  
pontocerebellar  hypoplasia,  1  presented  with  glaucoma.9  Normal  tension  glaucoma  is  
associated  with  polymorphisms  in  the  OPA1  gene.44  Glaucoma  was  also  reported  in  
a  family  with  Wolfram  syndrome.45  There  are  indications  that  ND5  mutations  are  
associated  with  the  development  of  open-­angle  glaucoma.46  Glaucoma  in  
mitochondrial  disorders  may  be  accessible  to  treatment  with  drugs  or  surgery.  
  
Secondary  Ophthalmologic  Mitochondrial  Disorder  Manifestations  
  
Secondary  ophthalmologic  mitochondrial  disorder  manifestations  are  due  to  
affectation  of  the  extraocular  muscles,  the  eyelids,  the  vestibulum,  or  the  brain.  
  
Bulb  Motility  
The  most  frequent  abnormalities  affecting  bulb  motility  include  nystagmus  and  
strabismus.  They  may  occur  independent  of  each  other  or  together.  They  may  occur  
with  or  without  other  ocular  or  extraocular  mitochondrial  disorder  manifestations.  
  
Nystagmus  
Nystagmus  or  roving  eye  movements  can  be  due  to  central  nervous  system  or  
vestibular  involvement  in  mitochondrial  disorders  and  are  the  most  common  
ophthalmologic  manifestations  as  a  presenting  symptom  in  pediatric  mitochondrial  
disorder  patients.47  Nystagmus  has  been  reported  in  patients  with  Leigh  syndrome,  
Alpers-­Huttenlocher  disease,  and  Pearson  syndrome  (Tables  1  and  2).47  Gaze-­
evoked  nystagmus  has  been  described  in  a  single  patient  with  “LHON  plus”  who  not  
only  carried  the  m.11778G>A  primary  Leber  hereditary  optic  neuropathy  mutation  but  
also  the  m.3394T>C  mutation.48  Recording  of  eye  movements  in  MELAS  patients  
may  show  saccadic  dysmetria,  prolonged  saccadic  reaction  time,  impaired  
suppression  of  reflex  eye  movements,  prolonged  reaction  during  antisaccades,  
downbeat  nystagmus,  square  wave  jerks,  or  impaired  pursuit.49  Epilepsy  in  MELAS  
patients  may  manifest  as  epileptic  nystagmus,  impaired  smooth  pursuit,  or  temporary  
eye  deviation.74  Moreover,  nystagmus  has  been  reported  in  a  patient  carrying  a  point  
mutation  in  the  DGUOK  gene  who  additionally  presented  with  retinal  blindness.50  
Nystagmus  in  addition  to  retinitis  pigmentosa  was  also  reported  in  a  patient  with  
nonsyndromic  mitochondrial  disorder  due  to  the  m.15995G>A  mutation  in  the  
tRNA(Pro)  gene  manifesting  as  ataxia,  deafness,  and  leukoencephalopathy.51  In  a  
study  of  7  Czech  autosomal  dominant  optic  atrophy  patients,  nystagmus  was  part  of  
the  phenotype.52  Nystagmus  is  also  a  common  feature  of  ARSAL/ARSACS.53  In  a  
study  of  44  Chinese  patients  with  Leigh  syndrome,  nystagmus  was  found  in  14%.24  
Nystagmus  can  be  also  a  feature  of  Wolfram  syndrome,54  recessive  ataxia  (dystonia  
and  mild  cerebellar  ataxia)  syndrome,  or  mitochondrial  depletion  syndrome.55  Roving  
eye  movements  and  nystagmus  may  additionally  occur  in  nonsyndromic  
mitochondrial  disorders.42  Resolution  of  nystagmus  is  possible  for  those  cerebral  or  
vestibular  forms  that  respond  to  treatment.  
  
Strabismus  
In  a  study  of  44  Chinese  patients  with  Leigh  syndrome,  strabismus  was  the  most  
frequent  ophthalmologic  abnormality  and  present  in  41%  of  patients.24  Among  those  
with  strabismus,  13  had  exotropia  and  5  esotropia.24  Strabismus  was  also  reported  in  
some  patients  with  X-­linked  sideroblastic  anemia  with  ataxia.56  Divergent  strabismus  
has  been  reported  as  the  presenting  manifestation  in  25%  of  juvenile  mitochondrial  
disorders.47  In  a  study  of  14  patients  with  pontocerebellar  hypoplasia,  of  which  13  
carried  a  CASK  mutation,  2  presented  with  strabismus.9  Strabismus  has  been  
reported  also  in  other  patients  with  pontocerebellar  hypoplasia,  without  knowing  the  
underlying  mutation.57,58  In  a  child  with  a  large  mitochondrial  DNA  deletion,  the  initial  
presentation  at  birth  was  cataract  and  strabismus.14  He  later  developed  Leigh-­like  
pathologies  and  strokelike  episodes.14  Additionally,  strabismus  has  been  reported  in  
patients  with  nonsyndromic  mitochondrial  disorders  (Tables  1  and  2).47  In  some  
cases,  surgery  may  have  a  beneficial  effect  on  strabism.  
  
Mitochondrial  Disorder  Manifestations  of  the  Extraocular  Muscles  
Affectation  of  the  extraocular  muscles  in  mitochondrial  disorders  results  in  
progressive  external  ophthalmoplegia.  Progressive  external  ophthalmoplegia  is  a  
frequent  ophthalmologic  manifestation  of  mitochondrial  disorders.  It  may  be  
complete,  resulting  in  walled-­in  bulbs,  or  incomplete.  It  may  affect  all  directions  of  
bulb  movements  or  only  some  of  them.  It  may  affect  one  eye  or  both  eyes.  
Progressive  external  ophthalmoplegia  is  most  frequently  associated  with  single  or  
multiple  mitochondrial  DNA  deletions.  Single  mitochondrial  DNA  deletions  may  cause  
progressive  external  ophthalmoplegia,  Kearns-­Sayre  syndrome,  or  Pearson  
syndrome.27  Multiple  mitochondrial  DNA  deletions  going  along  with  progressive  
external  ophthalmoplegia  may  be  due  to  mutations  in  nuclear  genes  such  as  PEO1,  
POLG1,  SLC25A4,  RRM2B,  POLG2,  or  OPA1.27  Additionally,  progressive  external  
ophthalmoplegia  may  be  due  to  mitochondrial  DNA  point  mutations,  particularly  in  
transfer  RNA  (eg,  tRNA(Lys))  genes.27  Transfer  RNA  mutations  manifesting  with  
progressive  external  ophthalmoplegia  frequently  occur  sporadically  akin  to  
mitochondrial  DNA  deletions  and  can  be  detected  only  in  muscle.75  Progressive  
external  ophthalmoplegia  may  be  the  sole  manifestation  of  the  m.3243A>G  mutation,  
which  commonly  manifests  as  MELAS  syndrome.59  Upward  gaze  was  reduced  in  2  
patients  with  mitochondrial  disorder.60  Progressive  external  ophthalmoplegia  was  a  
phenotypic  feature  in  a  patient  with  mitochondrial  neurogastrointestinal  
encephalomyopathy,8  Wolfram  syndrome,54  Leigh  syndrome,  autosomal  dominant  
optic  atrophy,  and  mitochondrial  recessive  ataxia  syndrome.61  Progressive  external  
ophthalmoplegia  has  been  also  described  in  MERRF  syndrome.62  Infantile-­onset  
spinocerebellar  ataxia  is  a  Finnish  disease,  and  some  of  the  24  cases  reported  so  far  
developed  ophthalmoplegia.63  A  hallmark  of  the  sensory  ataxic  neuropathy  with  
dysarthria  and  ophthalmoparesis  syndrome  is  ophthalmoparesis.64  Sensory  ataxic  
neuropathy  with  dysarthria  and  ophthalmoparesis  is  due  to  mutations  in  either  the  
POLG1  or  PEO1  gene  resulting  in  multiple  mitochondrial  DNA  deletions.64  
Additionally,  ophthalmoparesis  can  be  found  in  mitochondrial  depletion  syndrome65  or  
patients  with  nonsyndromic  mitochondrial  disorders.66  Ultrastructural  changes  on  
muscle  biopsy  from  extraocular  muscles  are  clearly  different  in  patients  with  Leber  
hereditary  optic  neuropathy  and  progressive  external  ophthalmoplegia.76  
  
Mitochondrial  Disorder  Manifestations  of  the  Eyelid  
One  of  the  most  frequent  mitochondrial  disorder  manifestations  is  ptosis  (Figure  2).  It  
may  occur  unilaterally  at  onset  but  usually  becomes  bilateral  during  the  disease  
course.  Ptosis  may  be  the  sole  manifestation  of  a  mitochondrial  disorder,  particularly  
at  onset  of  the  disease,  or  associated  with  other  manifestations.  Ptosis  may  show  
dynamic  alterations  specifically  at  onset  of  the  disease,  giving  rise  to  
misinterpretation  as  myasthenia  gravis.77  Particularly  at  onset,  ptosis  may  be  discrete  
such  that  it  is  missed  on  clinical  exam.  Ptosis  may  be  associated  with  progressive  
external  ophthalmoplegia  or  other  ocular  manifestations  of  a  mitochondrial  disorder.  
Ptosis  may  be  a  phenotypic  manifestation  in  syndromic  as  well  as  nonsyndromic  
mitochondrial  disorders.  Among  the  syndromic  mitochondrial  disorders,  ptosis  has  
been  particularly  reported  in  progressive  external  ophthalmoplegia,  MELAS,  MERRF,  
Kearns-­Sayre  syndrome,  sensory  ataxic  neuropathy  with  dysarthria  and  
ophthalmoparesis,67  Pearson  syndrome,  mitochondrial  neurogastrointestinal  
encephalomyopathy,  and  autosomal  dominant  optic  atrophy  (Table  2).19  In  a  study  of  
44  Chinese  patients  with  Leigh  syndrome,  ptosis  was  present  in  16%.24  Isolated  
cases  with  maternally  inherited  deafness  and  diabetes,60  mitochondrial  
neurogastrointestinal  encephalomyopathy,8  or  mitochondrial  depletion  syndrome68  
also  presented  with  ptosis.  In  a  Persian  Jew  with  mitochondrial  myopathy,  lactic  
acidosis,  and  sideroblastic  anemia  due  to  a  PUS1  mutation,  weak  lid  closure  was  




Madarosis  (alopecia  of  eyelashes)  is  an  extremely  rare  mitochondrial  disorder  
manifestation  and  has  been  reported  only  in  1  patient  so  far.79  Alopecia  of  the  
eyebrows  occasionally  occurs  in  patients  with  nonsyndromic  mitochondrial  disorders  
(Finsterer  J,  MD,  PhD,  KAR,  Vienna,  Austria)  but  has  not  been  reported  in  patients  
with  syndromic  mitochondrial  disorders.  Blepharospasm,  a  form  of  focal  dystonia,  
may  be  also  a  rare  manifestation  of  nonsyndromic  mitochondrial  disorders.80  
  
Mitochondrial  Disorders  Primarily  Manifesting  in  the  Eye  
There  are  a  few  syndromic  mitochondrial  disorders  that  primarily  present  with  
ophthalmologic  manifestations.  Among  these  are  Leber  hereditary  optic  neuropathy  
and  autosomal  dominant  optic  atrophy.  Thus,  both  are  described  in  more  detail  
below.  
  
Leber  Hereditary  Optic  Neuropathy  
Leber  hereditary  optic  neuropathy  is  a  maternally  inherited  blinding  disorder  due  to  
mutations  in  genes  encoding  for  subunits  of  respiratory-­chain  complex  I.  Mutations  in  
3  genes  account  for  almost  90%  of  all  Leber  hereditary  optic  neuropathy  cases.35  
The  3  most  prevalent  Leber  hereditary  optic  neuropathy  mutations  (primary  Leber  
hereditary  optic  neuropathy  mutations)  include  the  m.3460A>G  mutation  in  the  ND1  
gene,  the  m.11778G>A  mutation  in  the  ND4  gene,  and  the  m.14484T>C  mutation  in  
the  ND6  gene.35  Clinically,  Leber  hereditary  optic  neuropathy  is  characterized  by  
bilateral,  painless,  subacute  visual  failure  that  develops  during  young  adult  life.81  
Leber  hereditary  optic  neuropathy  is  4  to  5  times  more  frequent  in  males  compared  
with  females.  Affected  individuals  are  usually  entirely  asymptomatic  until  they  
develop  visual  blurring  affecting  the  central  visual  field  in  1  eye.81  Similar  symptoms  
occur  in  the  other  eye  an  average  of  2  to  3  months  later.  Visual  acuity  is  severely  
reduced  to  counting  fingers  or  even  worse  in  the  majority  of  cases,  and  visual  field  
testing  shows  an  enlarging  dense  central  or  ceco-­central  scotoma.81  After  the  acute  
phase,  the  optic  discs  become  atrophic.  Funduscopic  findings  typical  for  Leber  
hereditary  optic  neuropathy  include  microangiopathy,  hyperemic  discs,  retinal  
telangiectasias  (ectatic  capillaries),  peripapillary  microangiopathy,  and  tortuosity  of  
vessels  (twisted  vessels)  (Figure  3).  MRI  of  the  orbita  may  show  atrophy  of  the  nerve  
with  compensatory  widening  of  the  space  below  the  optic  sheath.  Mutations  in  the  
mitochondrial  ND3,  ND4,  or  ND6  genes  may  cause  Leber  hereditary  optic  
neuropathy  with  dystonia.82  Currently,  there  is  no  effective  treatment  available.  
  
Autosomal  Dominant  Optic  Atrophy  
Autosomal  dominant  optic  atrophy  is  a  blinding  disorder,  which,  unlike  Leber  
hereditary  optic  neuropathy,  does  not  exhibit  a  gender  bias.34  It  is  due  to  mutations  in  
the  nuclearly  encoded  OPA1  gene.34  Autosomal  dominant  optic  atrophy  also  may  be  
due  to  OPA3  mutations,  which  go  along  with  cataract.17  Autosomal  dominant  optic  
atrophy  is  clinically  characterized  by  progressive,  painless,  bilaterally  symmetric  
visual  loss.27  The  most  frequent  visual  field  abnormalities  in  autosomal  dominant  
optic  atrophy  are  central,  ceco-­central,  or  para-­central  scotomas  consistent  with  early  
involvement  of  the  papillo-­macular  bundle.27  Optic  disc  atrophy  may  be  subtle,  
diffuse,  or  present  as  temporal  “wedge”  defect.83,84  In  some  families,  OPA1  mutations  
may  not  only  manifest  with  optic  atrophy  but  also  with  progressive  external  
ophthalmoplegia,  ptosis,  and  hypoacusis.85  Because  glaucoma  neuropathy,  
autosomal  dominant  optic  atrophy,  and  Leber  hereditary  optic  neuropathy  
occasionally  present  with  similar  topographic  optic  disc  changes,  they  cannot  be  




This  review  shows  that  ophthalmologic  involvement  in  mitochondrial  disorders  is  
frequent,  variable,  and  diverse.  Among  primary  ophthalmologic  manifestations  of  
mitochondrial  disorders,  cataract,  pigmentary  retinopathy,  and  optic  atrophy  appear  
to  be  the  most  frequent,  and  among  the  secondary  manifestations  it  is  progressive  
external  ophthalmoplegia,  ptosis,  and  nystagmus.  Rare  ophthalmologic  
manifestations  of  mitochondrial  disorders  include  glaucoma,  choroidal  abnormalities,  
strabismus,  macular  degeneration,  abnormalities  of  the  ciliary  body,  or  corneal  
lesions.  Ocular  abnormalities  in  mitochondrial  disorders  may  occur  isolated  or  may  
occur  in  association  with  other  organ  manifestations  of  a  mitochondrial  disorder.  
Organs  other  than  the  eyes  affected  in  mitochondrial  disorders  include  the  muscles,  
nerves,  central  nervous  system,  endocrine  organs,  heart,  gastrointestinal  tract,  
kidneys,  bone  marrow,  skin,  or  the  bones.  Involvement  of  the  central  nervous  system  
or  the  vestibular  system  may  secondarily  affect  the  eyes.  Ocular  abnormalities  may  
dominate  the  phenotype,  such  as  in  Leber  hereditary  optic  neuropathy,  progressive  
external  ophthalmoplegia,  or  autosomal  dominant  optic  atrophy  or  may  be  
nondominant.  If  ophthalmologic  manifestations  are  mild  or  if  other  more  dominant  
features  prevail,  ophthalmologic  abnormalities  may  be  missed.  Ocular  abnormalities  
may  be  accessible  to  therapy  or  may  be  inaccessible  to  treatment.  Ophthalmologic  
involvement  in  mitochondrial  disorders  needs  to  be  appreciated  because  there  is  
appropriate  cure  available  in  some  cases,  which  strongly  determines  the  outcome.  
Blepharospasm  responds  favorably  to  botulinum  toxin,  surgery  can  be  beneficial  for  
ptosis,  ophthalmoparesis,  strabismus,  glaucoma,  or  cataract,  and  drugs  may  be  
effective  for  glaucoma,  or  central  nervous  system  or  vestibular  causes  of  nystagmus.  
Inaccessible  to  treatment  are  retinitis  pigmentosa,  optic  atrophy,  or  abnormalities  of  
the  ciliary  body  or  the  choroidea.  Recognizing  ophthalmologic  abnormalities  in  
mitochondrial  disorders  is  also  important  to  differentiate  them  from  causes  other  than  
mitochondrial  disorder.  
Ophthalmologists  should  not  only  look  into  but  also  around  the  eyes  of  a  
mitochondrial  disorder  patient.  Each  physician  involved  in  the  management  of  
mitochondrial  disorder  patients  must  have  a  close  look  into  the  eyes  of  their  patients.  
Ophthalmologic  complaints  must  be  taken  seriously  and  must  be  followed  up  and  
assessed  until  an  appropriate  diagnosis  has  been  established.  Ophthalmologic  
manifestations  of  mitochondrial  disorders  may  go  undiagnosed  if  the  abnormality  is  
subclinical  or  mild.  Ophthalmologic  symptoms  that  patients  with  mitochondrial  
disorders  may  report  include  visual  impairment,  blurring,  clouding,  photophobia,  
double  vision,  visual  field  defects,  tear-­dropping,  dry  eyes,  lid  drop,  loss  of  eyelashes  
or  eyebrows,  ocular  pain  at  rest  or  at  bulb  movement,  vertigo,  or  headache.  Ocular  
symptoms  can  be  easily  retrieved,  and  an  orientating  ophthalmologic  investigation  
can  be  carried  out  by  each  physician.  Simple  tests  for  visual  acuity,  double  vision,  
field  defects,  nystagmus,  pupillary  reactions,  or  voluntary  or  pursuit  eye  movements  
can  be  carried  out.  More  sophisticated  investigations  should  be  reserved  for  the  
ophthalmologist.  
In  conclusion,  this  review  about  ophthalmologic  manifestations  in  mitochondrial  
disorders  shows  that  the  eye  is  frequently  affected  in  syndromic  as  well  as  
nonsyndromic  mitochondrial  disorders.  Primary  and  secondary  ophthalmologic  
manifestations  can  be  differentiated.  The  most  frequent  ophthalmologic  
manifestations  of  mitochondrial  disorders  include  ptosis,  progressive  external  
ophthalmoplegia,  optic  atrophy,  retinopathy,  cataract,  and  nystagmus.  It  is  important  
to  recognize  and  diagnose  ophthalmologic  manifestations  of  mitochondrial  disorders  
because  they  may  lead  to  the  diagnosis  of  the  mitochondrial  disorder,  and  some  of  
them  are  accessible  to  symptomatic  treatment  with  partial  or  complete  short-­term  or  
long-­term  beneficial  effect.  If  the  neurologist  is  alert  to  ophthalmologic  symptoms  and  
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Figure  1.  Fluorescein  angiography  showing  blocking  of  background  fluorescence  in  
areas  of  hyperpigmentation  and  hyperfluorescence  due  to  a  retinal  pigment  
epithelium  window  defects  in  the  depigmented  areas  (A,  B).    
	  
	  
Fluorescein  angiography  showing  blocking  of  background  fluorescence  in  areas  of  
hyperpigmentation  and  hyperfluorescence  due  to  a  retinal  pigment  epithelium  
window  defects  in  the  depigmented  areas  (A,  B).  On  spectral  domain  optical  
coherence  tomography  scans  taken  through  the  planes  indicated  by  the  green  
arrows,  hyperpigmented  areas  corresponding  to  a  hyperreflective  dome-­shaped  
lesion  that  seemed  to  originate  from  the  retinal  pigment  epithelium  are  shown  (blue  
arrows)  (C,  D).  
	   	  
Figure  2.  A  58-­year-­old  man  with  genetically  unconfirmed  Kearns-­Sayre  syndrome  
who  had  developed  slowly  progressive  bilateral  ptosis  since  age  32  years.    
  
  
A  58-­year-­old  man  with  genetically  unconfirmed  Kearns-­Sayre  syndrome  who  had  
developed  slowly  progressive  bilateral  ptosis  since  age  32  years.  He  had  undergone  
a  first  surgical  ptosis  correction  at  age  46  years  but  experienced  a  relapse  already  1  
year  later.  He  underwent  a  second  ptosis  correction  on  the  right  side  at  age  58  years.  
	   	  
Figure  3.  Funduscopy  of  a  patient  carrying  the  mitochondrial  DNA  mutation  
m.13042G>A  in  the  ND5  gene  showing  complete  optic  atrophy  and  retinopathy  
characterized  by  yellowish  dots  in  the  retinal  pigmented  epithelium  with  peripheral  
distribution  (left).    
  
  
Funduscopy  of  a  patient  carrying  the  mitochondrial  DNA  mutation  m.13042G>A  in  
the  ND5  gene  showing  complete  optic  atrophy  and  retinopathy  characterized  by  
yellowish  dots  in  the  retinal  pigmented  epithelium  with  peripheral  distribution  (left).  
Complete  optic  atrophy  and  retinopathy  with  confluent  yellowish  dots  at  the  fovea  
and  macula  were  also  seen  in  the  patient’s  brother  (right).  In  addition  to  the  Leber  
hereditary  optic  neuropathy–like  optic  neuropathy  and  retinopathy,  the  phenotype  
included  cataract,  strokes,  miscarriages,  and  sudden  death.  
  
